After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care

By
Anna Zucker
May 28, 2026
0 min

Journal Of Medical Internet Research (Jmir)

Overview

Telehealth platforms have improved access to GLP-1 medications for obesity, facilitating quicker prescriptions. However, the lack of integrated clinical support may lead to adverse outcomes such as lean tissue loss and micronutrient deficiencies.

Background

Obesity affects 40% of Americans and is linked to serious health conditions like hypertension and type 2 diabetes. GLP-1 medications represent a significant advancement in obesity treatment, yet their effectiveness can be compromised without proper nutritional and behavioral support. The rise of telehealth has made these medications more accessible, but it has also highlighted a gap in comprehensive patient care.

Data Highlights

No numerical data presented in the source material.

Key Findings

Telehealth platforms have increased access to GLP-1 medications, aiding weight loss for many patients.
Research indicates that some patients experience loss of lean tissue and micronutrient deficiencies due to insufficient clinical support.
Integration of registered dietitians into telehealth programs can enhance patient outcomes by promoting sustainable lifestyle changes.
Patients on GLP-1 medications may face risks of inadequate protein intake and dietary quality without clinical guidance.
Cost remains a barrier for self-pay patients, affecting their ability to achieve optimal weight loss outcomes.

Clinical Implications

Healthcare providers should consider incorporating registered dietitians into telehealth programs to provide comprehensive support for patients on GLP-1 medications. Monitoring nutritional intake and addressing potential deficiencies is crucial for optimizing patient outcomes.

Conclusion

While telehealth has expanded access to GLP-1 medications, it is essential to address the accompanying lack of clinical support to ensure safe and effective weight management.